Research into the role of tyrosine kinase inhibitors in EGFR gene mutations has greatly improved the prognosis of lung cancer patients with EGFR activating mutation6, 7 and with the development of molecular targeted drug research, except for EGFR mutation, many other types of targeted gene aberrations have been identified, including HER2,8BRAF,9KRAS mutations,10 and ALK rearrangement.11 The gene discussed is ALK; the disease is lung cancer.